SUPERIOR PROTEINURIA REDUCTION WITH SPARSENTAN IN IMMUNOGLOBULIN A NEPHROPATHY (IGAN): A PROTECT STUDY INTERIM ANALYSIS

被引：0
|
作者：
Barratt, Jonathan [1 ]
Heerspink, Hiddo Lambers [2 ,3 ]
Wong, Muh [2 ,4 ]
Komers, Radko [5 ]
Mercer, Alex [6 ]
Radhakrishnan, Jai [7 ]
机构：
[1] Univ Leicester, Gen Hosp, Leicester, England
[2] Concord Repatriat Gen Hosp, Concord, Australia
[3] Univ Med Ctr Groningen, Groningen, Netherlands
[4] Univ Sydney, Concord Clin Sch, Camperdown, Australia
[5] Travere Therapeut Inc, San Diego, CA USA
[6] JAMCO Pharma Consulting, Enskede, Sweden
[7] Columbia Univ, New York, NY USA
来源：
NEPHROLOGY DIALYSIS TRANSPLANTATION | 2023年 / 38卷
关键词：
D O I：
暂无
中图分类号：
R3 [基础医学]; R4 [临床医学];
学科分类号：
1001 ; 1002 ; 100602 ;
摘要：
4057
引用
收藏
页码：I23 / I24
页数：2
相关论文
共 50 条
  • [1] PROTEINURIA REDUCTION WITH SPARSENTAN IN IMMUNOGLOBULIN A NEPHROPATHY (IGAN): PROTECT STUDY INTERIM RESULTS
    Radhakrishnan, Jai
    Wong, Muh Geot
    Heerspink, Hiddo J. L.
    Komers, Radko
    Prasad, Andy
    Mercer, Alex
    [J]. AMERICAN JOURNAL OF KIDNEY DISEASES, 2023, 81 (04) : S97 - S97
  • [2] Interim analysis indicates sparsentan PROTECTs in IgAN
    Susan J. Allison
    [J]. Nature Reviews Nephrology, 2023, 19 : 359 - 359
  • [3] Interim analysis indicates sparsentan PROTECTs in IgAN
    Allison, Susan J.
    [J]. NATURE REVIEWS NEPHROLOGY, 2023, 19 (06) : 359 - 359
  • [4] Pivotal Results of the Phase 3 PROTECT Trial of Sparsentan (SPAR) vs. Irbesartan (IRB) in Patients with Immunoglobulin A Nephropathy (IgAN)
    Busch, Martin
    [J]. INNERE MEDIZIN, 2024, 65 : S147 - S148
  • [5] IgA Nephropathy Patient Baseline Characteristics in the Sparsentan PROTECT Study
    Barratt, Jonathan
    Rovin, Brad
    Wong, Muh Geot
    Alpers, Charles E.
    Bieler, Stewart
    He, Ping
    Inrig, Jula
    Komers, Radko
    Heerspink, Hiddo J. L.
    Mercer, Alex
    Noronha, Irene L.
    Radhakrishnan, Jai
    Rheault, Michelle N.
    Rote, William
    Trachtman, Howard
    Trimarch, Hernan
    Perkovic, Vlado
    PROTECT Investigators
    [J]. KIDNEY INTERNATIONAL REPORTS, 2023, 8 (05): : 1043 - 1056
  • [6] Sparsentan: the first and only non-immunosuppressive therapy for the reduction of proteinuria in IgA nephropathy
    Trachtman, Howard
    Komers, Radko
    Inrig, Jula
    [J]. EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2024, 20 (06) : 571 - 576
  • [7] EFFICACY AND SAFETY OF IPTACOPAN IN PATIENTS WITH IGA NEPHROPATHY (IGAN): INTERIM ANALYSIS (IA) OF THE PHASE 3 APPLAUSE-IGAN STUDY
    Rizk, Dana V.
    Kollins, Dmitrij
    Papachristofi, Olympia
    Hach, Thomas
    Jacinto-Sanders, Severina
    Merkel, Tobias
    Renfurm, Ronny
    Perkovic, Vlado
    [J]. AMERICAN JOURNAL OF KIDNEY DISEASES, 2024, 83 (05) : 699 - 700
  • [8] SPARSENTAN (SPAR) SHOWS CLINICALLY MEANINGFUL TREATMENT EFFECTS VS IRBESARTAN (IRB) IN PATIENTS WITH IGA NEPHROPATHY (IGAN) IN THE PHASE 3 PROTECT TRIAL
    Rovin, Brad
    Barratt, Jonathan
    Murphy, Edward
    Geletka, Rob
    Komers, Radko
    Perkovic, Vlado
    [J]. AMERICAN JOURNAL OF KIDNEY DISEASES, 2024, 83 (04) : S114 - S114
  • [9] Clinical and immunohistochemical study of immunoglobulin A nephropathy (IgAN) before and after tonsillectomy
    Abe, K
    Miyazaki, M
    Shioshita, K
    Harada, T
    Koji, T
    Kohno, S
    [J]. ACTA OTO-LARYNGOLOGICA, 2004, 124 : 20 - 24
  • [10] COVID VACCINE RESPONSES DURING SIBEPRENLIMAB TREATMENT OF IGA NEPHROPATHY (IGAN): AN INTERIM ANALYSIS
    Mccafferty, Kieran
    Follman, Kristin
    Pasetti, Marcela
    Schachter, Asher
    Mathur, Mohit
    Diane, M. A.
    Yarbrough, Jill
    Shriver, Mallory
    Engler, Frank
    Oldach, David
    Suzuki, Yusuke
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2023, 38 : I17 - I17
12345